XEN45 Gel Stent Versus PRESERFLO MicroShunt: Two-Year Real-World Outcomes from a Swiss Single Center

Purpose: To compare the effectiveness and safety of XEN45 Gel Stent (XEN45) and PRESERFLO MicroShunt (PF) implantation in routine clinical practice over a 2-year follow-up period. Methods: This retrospective, single-center comparative study included 123 eyes from 109 patients undergoing ab interno XEN45 (58 eyes) or ab externo PF (65 eyes) implantation, either as standalone surgery or combined with phacoemulsification. Surgical success at 24 months required an intraocular pressure (IOP) of 6–21 mmHg, a reduction of ≥20% from baseline, and no secondary glaucoma surgery. Complete success required no IOP-lowering medication; qualified success allowed medication. Needling and open bleb revision were not classified as failures. Adjusted comparisons accounted for baseline IOP, previous glaucoma surgery, concomitant phacoemulsification, and within-patient clustering; medication analyses also adjusted for baseline medication count. Documented surgical failures were retained despite missing 24-month measurements. Results: Mean age at surgery was 76.1 ± 10.4 years in the XEN45 group and 73.2 ± 9.3 years in the PF group. Baseline IOP was higher in the XEN45 than in the PF cohort (27.3 ± 9.8 vs. 23.5 ± 9.9 mmHg; p = 0.046). At 24 months, mean IOP was 14.5 ± 4.7 mmHg after XEN45 and 13.6 ± 3.4 mmHg after PF (adjusted p = 0.447). Qualified surgical success was achieved in 30/48 (62.5%) and 20/31 (64.5%) evaluable eyes, respectively (adjusted p = 0.732), and complete success in 21/48 (43.8%) and 15/30 (50.0%) eyes (adjusted p = 0.570). The mean number of glaucoma medications at 24 months was 0.96 ± 1.29 after XEN45 and 0.48 ± 0.87 after PF (adjusted p = 0.075). Needling was more frequent following XEN45 than PF implantation (27/58 [46.6%] vs. 10/65 [15.4%]; adjusted p = 0.002). Shallow anterior chamber occurred in 8/58 (13.8%) versus 0/65 eyes, and implant dislocation in 8/58 (13.8%) versus 1/65 (1.5%). Differential missingness of 24-month IOP data (17.2% vs. 53.8%) limited the interpretation of the comparative results. Conclusions: Both procedures were associated with substantial reductions in IOP and medication burden over two years. No statistically significant differences in adjusted 24-month IOP or surgical success were detected. XEN45 was associated with a greater need for postoperative needling and numerically more shallow anterior chambers and implant dislocations. The substantial difference in incomplete follow-up limits comparative inference.

Authors

Institutions

Publication Details

Journal
Journal of Clinical Medicine
Published
2026-11-19
DOI
https://doi.org/10.3390/jcm15229065
Primary Topic
Glaucoma and retinal disorders
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

XEN45 Gel Stent Versus PRESERFLO MicroShunt: Two-Year Real-World Outcomes from a Swiss Single Center

Markus Tschopp, Marcel Nico Menke, Ανθία Παπάζογλου, Daniel Barthelmes et al.
Journal of Clinical Medicine
Glaucoma and retinal disorders
article

XEN45 Gel Stent Versus PRESERFLO MicroShunt: Two-Year Real-World Outcomes from a Swiss Single Center

Markus Tschopp, Marcel Nico Menke, Ανθία Παπάζογλου, Daniel Barthelmes, Anina Zeier
article en

Abstract

Purpose: To compare the effectiveness and safety of XEN45 Gel Stent (XEN45) and PRESERFLO MicroShunt (PF) implantation in routine clinical practice over a 2-year follow-up period. Methods: This retrospective, single-center comparative study included 123 eyes from 109 patients undergoing ab interno XEN45 (58 eyes) or ab externo PF (65 eyes) implantation, either as standalone surgery or combined with phacoemulsification. Surgical success at 24 months required an intraocular pressure (IOP) of 6–21 mmHg, a reduction of ≥20% from baseline, and no secondary glaucoma surgery. Complete success required no IOP-lowering medication; qualified success allowed medication. Needling and open bleb revision were not classified as failures. Adjusted comparisons accounted for baseline IOP, previous glaucoma surgery, concomitant phacoemulsification, and within-patient clustering; medication analyses also adjusted for baseline medication count. Documented surgical failures were retained despite missing 24-month measurements. Results: Mean age at surgery was 76.1 ± 10.4 years in the XEN45 group and 73.2 ± 9.3 years in the PF group. Baseline IOP was higher in the XEN45 than in the PF cohort (27.3 ± 9.8 vs. 23.5 ± 9.9 mmHg; p = 0.046). At 24 months, mean IOP was 14.5 ± 4.7 mmHg after XEN45 and 13.6 ± 3.4 mmHg after PF (adjusted p = 0.447). Qualified surgical success was achieved in 30/48 (62.5%) and 20/31 (64.5%) evaluable eyes, respectively (adjusted p = 0.732), and complete success in 21/48 (43.8%) and 15/30 (50.0%) eyes (adjusted p = 0.570). The mean number of glaucoma medications at 24 months was 0.96 ± 1.29 after XEN45 and 0.48 ± 0.87 after PF (adjusted p = 0.075). Needling was more frequent following XEN45 than PF implantation (27/58 [46.6%] vs. 10/65 [15.4%]; adjusted p = 0.002). Shallow anterior chamber occurred in 8/58 (13.8%) versus 0/65 eyes, and implant dislocation in 8/58 (13.8%) versus 1/65 (1.5%). Differential missingness of 24-month IOP data (17.2% vs. 53.8%) limited the interpretation of the comparative results. Conclusions: Both procedures were associated with substantial reductions in IOP and medication burden over two years. No statistically significant differences in adjusted 24-month IOP or surgical success were detected. XEN45 was associated with a greater need for postoperative needling and numerically more shallow anterior chambers and implant dislocations. The substantial difference in incomplete follow-up limits comparative inference.

Journal of Clinical MedicineVol. 15(22)
University of Bern (CH), The University of Sydney (AU), University of Zurich (CH), University Hospital of Bern (CH), University Hospital of Zurich (CH), Kantonsspital Aarau (CH)
Glaucoma and retinal disorders
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon